TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22300892
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous administration of IFN‐α2b
Study: 16011678
Drug: Maximum likelihood
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum likelihood estimator (MLE) for treatment assignment
Study: 16011678
Drug: Data from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data from a trial comparing two antipsychotics
Study: 7573997
Drug: Ephedrine infusion
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine infusion to increase systolic blood pressure by 20%
Study: 1659173
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation Therapy (RT) only
Study: 1659173
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation Therapy + Chemotherapy (RT + Chemo)
Study: 1659173
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation Therapy + Chemotherapy + Misonidazole (RT + Chemo/Miso)
Study: 28783867
Drug: Intravaginal ring
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal ring (IVR) releasing 1050 μg ATZ per day and 40 μg LNG per day with 400 mg miconazole administered on 3 consecutive evenings during treatment on days 9-11.
Study: 28783867
Drug: Intravaginal ring
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal ring (IVR) releasing 1050 μg ATZ per day and 40 μg LNG per day with 100 mg clindamycin administered on 3 consecutive evenings during treatment on days 9-11.
Study: 28783867
Drug: Intravaginal ring
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal ring (IVR) releasing 1050 μg ATZ per day and 40 μg LNG per day with 75 mg nonoxynol-9 administered on 3 consecutive evenings during treatment on days 9-11.
Study: 28783867
Drug: Intravaginal ring
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal ring (IVR) releasing 1050 μg ATZ per day and 40 μg LNG per day with tampon co-usage performed on days 20-23.
Study: 27314120
Drug: Fixed-on-2 (FO2)
Normalized name: Pyrrolid-2-one
DrugBank: Pyrrolidone (DB19152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-on-2 (FO2) implants
Study: 27314120
Drug: Fixed-on-3 (FO3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-on-3 (FO3) implants
Study: 11993095
Drug: Factor AF2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factor AF2 (500 mg i.v., given at days 0‐3, 7‐10 and 11‐14)
Study: 7532708
Drug: Granulocyte-colony stimulating
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony stimulating factor, 10 micrograms/kg intravenously, administered within 24 hours of birth and at 24-hour intervals for a maximum of three doses if neutropenia persisted
Study: 2214101
Drug: Coffee (275
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee (275 mg of caffeine)
Study: 24098692
Drug: Contraceptive implant
Normalized name: Implanon Contraceptive Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive implant
Study: 22340793
Drug: Negative-pressure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-pressure therapy from -19 kPa to -8 kPa, n = 10
Study: 22340793
Drug: Negative-pressure therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-pressure therapy, n = 10
Study: 15651517
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 20 cc (placebo)
Study: 10965244
Drug: 5.5-mm Acrysof
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.5-mm Acrysof lens implants through 3.2-mm outer and 4-mm inner temporal clear corneal openings (stretch incision)
Study: 10965244
Drug: 5.5-mm Acrysof
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.5-mm Acrysof lens implants
Study: 8986972
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of fentanyl (C)
Study: 8986972
Drug: Bolus dosing
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dosing of fentanyl (B)
Study: 8986972
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of fentanyl (C) in phase 2
Study: 8986972
Drug: Bolus dosing
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dosing of fentanyl (B) in phase 2
Study: 1618662
Drug: CT/RT (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT/RT (three cycles of cis‐platinum and 5‐FU chemotherapy followed by postoperative radiotherapy)
Study: 6208728
Drug: Anesthetic cream
Normalized name: DIBUCAINE/DIPERODON ANESTHETIC CREAM
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic cream with an eutectic mixture of 5% lidocaine and 5% prilocaine applied for 5-15 min.
Study: 6208728
Drug: Anesthetic cream
Normalized name: DIBUCAINE/DIPERODON ANESTHETIC CREAM
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic cream with an eutectic mixture of 5% lidocaine and 5% prilocaine applied for 30-60 min.
Study: 29624523
Drug: Weekly PP
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly PP exercises
Study: 17686672
Drug: Natural interferon
Normalized name: interferon beta natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural interferon treatment for further 16‐36 weeks (mean 23.7 weeks) after pegylated interferon + ribavirin treatment cessation.
Study: 17686672
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon + ribavirin treatment (before cessation).
Study: 17686672
Drug: Natural interferon
Normalized name: interferon beta natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural interferon treatment.
Study: 31796467
Drug: Novel screening
Normalized name: Novel influenza-H1N1-09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel screening program for gastric cancer using serologic tests of Helicobacter pylori antibodies and pepsinogens, and positive family history of gastric cancer in first‐degree relatives (FDR).
Study: 29284453
Drug: ST segment
Normalized name: ST-36
DrugBank: ST-36 (DB17275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST segment analysis (STan) monitoring as an adjunct to cardiotocography (CTG)
Study: 26024297
Drug: Blueberry smoothie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry smoothie (twice daily for six weeks)
Study: 26024297
Drug: Placebo smoothie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo smoothie (twice daily for six weeks)
Study: 15617954
Drug: Troglitazone 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 150 mg/d
Study: 15617954
Drug: Troglitazone 300
Normalized name: troglitazone 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 300 mg/d
Study: 9239526
Drug: Paclitaxel therapy
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel therapy at a dose of 175 mg/m2
Study: 9239526
Drug: Pretreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment with potentially neurotoxic drugs (cisplatin and carboplatin)
Study: 8108224
Drug: HbOC-DTP combined
Normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC-DTP combined vaccine
Study: 8108224
Drug: Separate injections
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injections of HbOC and DTP vaccines
Study: 20014980
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron supplementation (ferric carboxymaltose)
Study: 29538179
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation (ferrous sulfate)
Study: 26428942
Drug: 4 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 courses of cisplatin 100 mg/mq and paclitaxel 175 mg/mq every 21 days (Group A)
Study: 26428942
Drug: 6 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 courses of cisplatin 100 mg/mq and paclitaxel 175 mg/mq every 21 days (Group B)
Study: 23229241
Drug: 1.23% NaF-gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23% NaF-gel
Study: 14662662
Drug: Artichoke extract
Normalized name: artichoke extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artichoke extract (3 capsules)
Study: 14662662
Drug: Placebo (indistinguishable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (indistinguishable inert capsules)
Study: 11058673
Drug: Levomethadyl acetate
Normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levomethadyl acetate (75 to 115 mg)
Study: 11058673
Drug: Buprenorphine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (16 to 32 mg)
Study: 11058673
Drug: High-dose methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methadone (60 to 100 mg)
Study: 11058673
Drug: Low-dose methadone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methadone (20 mg)
Study: 1621669
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg ibuprofen therapy
Study: 1621669
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg acetaminophen therapy
Study: 1621669
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg ibuprofen therapy
Study: 1621669
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg ibuprofen therapy
Study: 6487947
Drug: Small dose
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small dose of alcohol (0.44 ml.kg‐1)
Study: 6487947
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of alcohol (0.88 ml.kg‐1)
Study: 6487947
Drug: Placebo (0.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.0 ml.kg‐1)
Study: 26751765
Drug: Inactivated Enterovirus
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated Enterovirus 71 vaccine
Study: 24929936
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (4 sessions of 1 hour per week for 2 weeks)
Study: 24929936
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (1 session of 1 hour per week for 8 weeks)
Study: 23585666
Drug: L-T3 (liothyronine)
Normalized name: L-T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-T3 (liothyronine)
Study: 23585666
Drug: L-T4 (levothyroxine)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-T4 (levothyroxine)
Study: 23585666
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg TRH dose
Study: 20937051
Drug: Furosemide IV
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide IV infusion + oral midodrine 15 mg administered 30 min before furosemide
Study: 20937051
Drug: Furosemide IV
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide IV infusion + oral placebo administered 30 min before furosemide
Study: 18384418
Drug: 0.5 microg
Normalized name: calcitriol 0.5 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 microg kg(‐1) min(‐1) glyceryl trinitrate (GTN) infusion over 20 min
Study: 12730416
Drug: +ISO (soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: +ISO (soy protein with 83 mg isoflavones)
Study: 16730418
Drug: ‐ISO (soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ‐ISO (soy protein with 3 mg isoflavones)
Study: 14680611
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA), 500 mg/day for 5 days
Study: 14680611
Drug: Mifepristone (MIF),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (MIF), 100 mg/day for 5 days
Study: 14680611
Drug: Mifepristone (MIF)
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone (MIF) + Medroxyprogesterone acetate (MPA), 100 mg/day + 500 mg/day for 5 days
Study: 2428269
Drug: 6% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethyl starch (10 ml/kg body weight)
Study: 2428269
Drug: 5.5% oxypolygelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.5% oxypolygelatin (10 ml/kg body weight)
Study: 2428269
Drug: 5.0% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0% human albumin (10 ml/kg body weight)
Study: 24629060
Drug: ISDN (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN (10 mg/ml, 1%)
Study: 20579405
Drug: Low-fat dairy
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat dairy consumption (500 ml low-fat milk and 150 g low-fat yogurt)
Study: 20579405
Drug: Carbohydrate-rich control
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-rich control products (600 ml fruit juice and three fruit biscuits)
Study: 16182039
Drug: 3-month oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month oral controlled diet followed by 3-month spontaneous dietary intake
Study: 11205423
Drug: Nasal Spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Spray
Study: 7904330
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (1,200 mg)
Study: 7904330
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of allopregnanolone and pregnanolone (> or = 95.55 nmol/l)
Study: 3030904
Drug: Bran biscuits
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bran biscuits (12 biscuits, 1 = 1.3 g fibre)
Study: 3030904
Drug: Placebo biscuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo biscuits (12 biscuits, 1 = 0.23 g fibre)
Study: 21142812
Drug: Losartan/HCTZ (50mg/12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan/HCTZ (50mg/12.5mg daily)
Study: 12953850
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (perindopril plus indapamide)
Study: 3039882
Drug: Acyclovir, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir, 5 mg/kg intravenously every 8 hours
Study: 25372219
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity laser therapy (LILT) - 790 nm, 30 mW continuous wave, 0.13 cm2 focal spot, applied energy of 3.6 J, fluence of 27.69 J/cm2
Study: 19863517
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg PTX‐SR (Apo‐Pentoxifylline, Apotex Inc.) twice daily for 6 months
Study: 6849741
Drug: Indoramin 25
Normalized name: indoramin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin 25 mg
Study: 8067273
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (mean 4106 lx)
Study: 8067273
Drug: Dim light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim light therapy (mean 96 lx)
Study: 3197677
Drug: Neurotol slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotol slow (slow-release carbamazepine), administered twice daily
Study: 3197677
Drug: Tegretol (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegretol (conventional carbamazepine), administered three times daily
Study: 29574518
Drug: Minodronate (MIN)
Normalized name: Minodronic acid
DrugBank: Minodronic acid (DB06548)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Minodronate (MIN) 50 mg once-monthly
Study: 29574518
Drug: Risedronate (RIS)
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronate (RIS) 75 mg once-monthly
Study: 14623651
Drug: Intravenous contrast-enhanced
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous contrast-enhanced indirect magnetic resonance arthrography
Study: 6605082
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment and Surgical treatment
Study: 26964825
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) at 125 mm Hg
Study: 26964825
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) at 75 mm Hg
Study: 26964825
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (leaving wounds open)
Study: 23958073
Drug: Cohen Flex-Tip
Normalized name: Ed Flex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohen Flex-Tip blocker
Study: 21250566
Drug: CPP-ACP containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP-ACP containing cream applied for 3 minutes once per day during a 3-week treatment period
Study: 21250566
Drug: Standard fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluoride toothpaste (1450 ppm F- as NaF) and abstaining from other oral hygiene products
Study: 15781506
Drug: Propofol and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol and remifentanil (bolus doses of propofol 3-5 mg/kg and remifentanil 1-4 microg/kg)
Study: 15781506
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with sevoflurane and nitrous oxide (propofol 3-5 mg/kg with 2%-8% sevoflurane and 70% nitrous oxide)
Study: 15175435
Drug: IFL plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFL plus bevacizumab (5 mg/kg every two weeks)
Study: 9305487
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg four times daily
Study: 7697690
Drug: Omeprazole (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (both doses)
Study: 3538987
Drug: sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual buprenorphine 200 mcg
Study: 3538987
Drug: sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual buprenorphine 400 mcg
Study: 29471124
Drug: Daily vitamin
Normalized name: Daily Vitamin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin D3 supplementation (400, 4000, or 10,000 IU)
Study: 23147684
Drug: Computer-based clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based clinical decision support with twice-monthly audits and printed management suggestions based on guideline-recommended blood pressure targets
Study: 2082484
Drug: Aspirin, 50
Normalized name: Aspirin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 50 mg t.i.d.
Study: 2082484
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus dipyridamole, 50 mg t.i.d. plus 75 mg t.i.d.
Study: 24959618
Drug: Sufentanil administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil administration at 0.15 ng · mL(‐1) until extubation
Study: 24959618
Drug: Sufentanil administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil administration
Study: 24959618
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administration (Control group)
Study: 22851805
Drug: SB‐649868 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB‐649868 (10, 30, 60 mg)
Study: 22851805
Drug: SB‐649868 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB‐649868 (60 mg)
Study: 20170699
Drug: Risperidone 6mg
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone 6mg daily
Study: 20170699
Drug: Olanzapine 20mg
Normalized name: OLANZAPINE 20MG TAB
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine 20mg daily
Study: 18945282
Drug: Alcohol-based oily
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol-based oily disinfectant gel containing 70% ethanol after regular hand washing
Study: 15832830
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) with 100% adherence
Study: 15832830
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) with at least 80% adherence
Study: 15832830
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) with < 80% adherence
Study: 12875727
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg CEE + 2 mg MPA + 1 tab Caltrate‐D per day (Group A)
Study: 12875727
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg CEE + 2 mg MPA + 1 tab Caltrate‐D per day (Group B)
Study: 10606110
Drug: Intravenous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enoxaparin (1 mg/kg bolus dose)
Study: 2145212
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with gamma-interferon (2 million units/m2)
Study: 6380897
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (100 mg suppositories)